首页> 外文期刊>Human Genetics >Mutation analysis in Bardet–Biedl syndrome by DNA pooling and massively parallel resequencing in 105 individuals
【24h】

Mutation analysis in Bardet–Biedl syndrome by DNA pooling and massively parallel resequencing in 105 individuals

机译:通过DNA合并和大规模平行重测序对105名个体进行的Bardet-Biedl综合征突变分析

获取原文
获取原文并翻译 | 示例
       

摘要

Bardet–Biedl syndrome (BBS) is a rare, primarily autosomal-recessive ciliopathy. The phenotype of this pleiotropic disease includes retinitis pigmentosa, postaxial polydactyly, truncal obesity, learning disabilities, hypogonadism and renal anomalies, among others. To date, mutations in 15 genes (BBS1–BBS14, SDCCAG8) have been described to cause BBS. The broad genetic locus heterogeneity renders mutation screening time-consuming and expensive. We applied a strategy of DNA pooling and subsequent massively parallel resequencing (MPR) to screen individuals affected with BBS from 105 families for mutations in 12 known BBS genes. DNA was pooled in 5 pools of 21 individuals each. All 132 coding exons of BBS1–BBS12 were amplified by conventional PCR. Subsequent MPR was performed on an Illumina Genome Analyzer II™ platform. Following mutation identification, the mutation carrier was assigned by CEL I endonuclease heteroduplex screening and confirmed by Sanger sequencing. In 29 out of 105 individuals (28%), both mutated alleles were identified in 10 different BBS genes. A total of 35 different disease-causing mutations were confirmed, of which 18 mutations were novel. In 12 additional families, a total of 12 different single heterozygous changes of uncertain pathogenicity were found. Thus, DNA pooling combined with MPR offers a valuable strategy for mutation analysis of large patient cohorts, especially in genetically heterogeneous diseases such as BBS.
机译:Bardet-Biedl综合征(BBS)是一种罕见的,主要是常染色体隐性纤毛病。这种多效性疾病的表型包括色素性视网膜炎,多轴后多轴性,截断性肥胖,学习障碍,性腺功能减退和肾异常等。迄今为止,已经描述了导致BBS的15个基因(BBS1-BBS14,SDCCAG8)中的突变。广泛的遗传基因座异质性使得突变筛选既费时又昂贵。我们应用了DNA合并和随后的大规模并行重测序(MPR)的策略,以筛选来自105个家庭的受BBS影响的个体中12个已知BBS基因的突变。将DNA汇集在5个集合中,每个集合21个人。通过常规PCR扩增了BBS1–BBS12的所有132个编码外显子。随后的MPR在Illumina Genome Analyzer II™平台上进行。突变鉴定后,通过CEL I核酸内切酶异源双链体筛选分配突变载体,并通过Sanger测序确认。在105个个体中的29个个体(占28%)中,在10个不同的BBS基因中都鉴定出了两个突变的等位基因。总共确认了35种不同的致病突变,其中18种是新颖的突变。在另外12个家庭中,总共发现了12种不确定的致病性的单一杂合变化。因此,DNA池与MPR相结合为大型患者群体的突变分析提供了一种有价值的策略,尤其是在遗传异质性疾病(例如BBS)中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号